Evidence map›Paper›PMID 40196215›Full record

ArticleOTO open

Ototoxicity Monitoring: The Evolution of a Protocol for Head and Neck Cancer Patients.

Jena Patel, Jacob Beiriger, Kalena Liu, Zach Urdang, Julia Croce, Molly Wolfson, Jacob Hulswit, Olivia Giglio, Jacob B Hunter, Irina Middleton

Abstract read
In one paragraph

Article in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jena PatelDepartment of Otolaryngology-Head and Neck Surgery Thomas Jefferson University Philadelphia Pennsylvania USA.ORCID 0000-0002-4609-3631
Jacob BeirigerSidney Kimmel Medical College Thomas Jefferson University Philadelphia Pennsylvania USA.
Kalena LiuDepartment of Otolaryngology-Head and Neck Surgery Thomas Jefferson University Philadelphia Pennsylvania USA.
Zach UrdangDepartment of Otolaryngology-Head and Neck Surgery Thomas Jefferson University Philadelphia Pennsylvania USA.
Julia CroceDepartment of Otolaryngology-Head and Neck Surgery Thomas Jefferson University Philadelphia Pennsylvania USA.
Molly WolfsonDepartment of Otolaryngology-Head and Neck Surgery Thomas Jefferson University Philadelphia Pennsylvania USA.
Jacob HulswitDepartment of Otolaryngology-Head and Neck Surgery Thomas Jefferson University Philadelphia Pennsylvania USA.
Olivia GiglioDepartment of Otolaryngology-Head and Neck Surgery Thomas Jefferson University Philadelphia Pennsylvania USA.
Jacob B HunterDepartment of Otolaryngology-Head and Neck Surgery Thomas Jefferson University Philadelphia Pennsylvania USA.
Irina MiddletonDepartment of Otolaryngology-Head and Neck Surgery Thomas Jefferson University Philadelphia Pennsylvania USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: We evaluated an ototoxicity monitoring program (OMP) for improving audiologic follow-up in head and neck cancer (HNC) patients. Study Design: Retrospective cohort study. Setting: Tertiary academic center. Methods: Two hundred and forty patients were recommended for chemotherapy between January 2017 and June 2022. An OMP was implemented in March 2021; every patient received an audiology referral and was contacted to schedule a pretreatment audiogram. Patients were divided into pre-OMP and post-OMP cohorts. Main outcome measures included rates of pretreatment audiograms, posttreatment audiograms, posttreatment otologic symptoms, and hearing aid utilization. Results: There were 131 patients evaluated pre-OMP and 109 evaluated post-OMP. The mean age for all patients was 62.8 ± 11.9 years; 76.3% were male. After the implementation of the OMP, a significantly higher proportion of patients received a pretreatment audiogram (66.1% vs 34.4%, Conclusion: Implementation of an OMP significantly improved the proportion of HNC patients that underwent pretreatment audiograms prior to systemic therapy; however, audiologic follow-up remained largely unchanged in the posttreatment period. Level of Evidence: Level 4.

Indexed as

cisplatinhead and neck cancerototoxicity monitoring

Identifiers

PMID40196215
PMCPMC11973582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.